Novel results from the CLAIM study demonstrate better pulmonary ventilation/perfusion match and ventilation dynamics when hyperinflated chronic obstructive pulmonary disease (COPD) patients are treated with indacaterol/glycopyrronium.
Dual bronchodilation in combination with a long-acting β agonist and a muscarinic receptor antagonist was found to decline hyperinflation and increase heart function in the CLAIM trial . The study included 62 COPD patients with hyperinflation expressed by a residual volume of >135% at baseline. All patients were ≥40 years old and had smoked for ≥10 pack-years. The new investigation analysed treatment effects on pulmonary ventilation/perfusion match (VQM) and regional ventilation dynamics by comparing indacaterol/glycopyrronium versus placebo in the CLAIM cohort .
Participants were randomised 1:1. Group 1 first received indacaterol/glycopyrronium at a dosage of 110/50 μg per day for 14 days followed by another ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Holistic View on Asthma Next Article
Alternative Nicotine Delivery Products: No Help in Smoking Cessation »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.